William Blair initiates coverage of digital finance stocks
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
William Blair initiated coverage of Sterling Infrastructure (STRL) with an Outperform rating.Stay Ahead of the Market:Discover outperforming ...
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
Stock Trading Recap. On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a modest uptick, ending the day at $1.4 which represents a slight increase ...
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
CHICAGO, January 07, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named Stewart ...
BofA Securities has recently reduced FibroGen Inc (FGEN) stock to Underperform rating, as announced on August 8, 2023, according to Finviz. Earlier, on June 26, 2023, William Blair had reduced the ...
Enfusion (ENFN – Research Report) received a Hold rating and price target from William Blair analyst Dylan Becker today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback